Promising results were observed in a phase I/II clinical trial (NCT00902044) involving HER2-CAR-T cells for the treatment of 19 patients with HER2-positive sarcomas, including osteosarcomas, primitive neuroectodermal tumors, Ewing sarcoma, and protofibroblastic small round cell tumors. Here, ERBB2 is linked to Ewing sarcoma.